What I have found interesting is the mention of the 3rd

New Post Public Reply Private Reply Replies (1) Message Board
Mauibound
517
What I have found interesting is the mention of the 3rd party Tax Software as well as expense tracking.

Rory spoke about it in the Q2 call. He referenced the Q1 call where he said he had brought it up.

I looked at the Q1 call and saw he spoke more about the revenue share and how it was going to work and that they were finalizing deals rather than who the deals were with.

It was in the July 13th prospectus where it gave more context within the In APP EcoSystem.

The EcoSystem has not been on the back burner.
They have partners they are bundling with already

Q1 Call Transcript

Some of you longstanding stockholders may recall some early talk about the development of our own ecosystem, or App Store, essentially a tab in our app through which users could subscribe for complementary apps or upgraded features and functionality. The purpose was to generate greater revenue per user from our existing user base, which has grown considerably over this past year. Well, in order to execute that strategy, we needed to develop and deploy in-app purchase capability for each user. I'm proud to say that we've now finished that development and we are currently executing agreements with other app developers, who will market their application to our users directly through our app on a revenue share basis with us, not unlike what Apple and Salesforce do. We plan to announce those relationships in the coming week.

Taking that a step further, we are releasing an open API that will allow third-party developers to develop applications, features and functionality that will integrate seamlessly into our platform that they will market directly to our users to our app, also on a revenue share basis. And because we now have such a large number of users who have downloaded our application, we have become an attractive and easily addressable market for third-party developers. And that is all very high margin, virtually no cost revenue for us.

As to the number of potential users to which the developers can market their products, and why we are in attractive addressable market, let me share the data on user downloads. As you may recall, in the third quarter of 2019, we reported approximately 825,000 users. Well through the end of April 2020 we have approximately 1.4 million users representing growth of approximately 475,000 users or 67% since Q3 2019, and growth of 150% over the past 12 months.

July 13th PDF Form FWPFiling 

The Verb In-App Purchase Ecosystem
Introducing Our New In-App Purchase Feature
Monetizes Our Large User Base / Increases ARPU
Allows users to:
Pay for subscriptions directly in the app to access upgraded verbCRM features
Access our forthcoming “App Store” where users can subscribe for third-party apps chosen to appeal to the verbCRM user demographic, such as:

Specialized expense tracking, tax software, and other third-party apps
An “Open API” architecture will also allow third-party developers to create specialized apps with features and functionality that integrate seamlessly into our verbCRM application

Offered directly to our large user base on a revenue-sharing basis

Verb Technology Company, Inc. (NASDAQ: VERB) © 2020 18


Q2 2020 Results - Earnings Call Transcript
Aug. 14, 2020

We're also making progress on our own app store ecosystem that I referenced in our last earnings call that we are about to release a bundled service offering, which includes a higher priced version of our verbCRM app bundled with third-party tax app software for sales professionals. 


So, another very strong vertical added plus an additional revenue stream.

Compound revenue.

Aloha

TON Strategy Co. (TONX) Stock Research Links

TONX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Understanding Rollins' Current Market Position and Outlook

Updated Category News Views 226

Analyzing Rollins Inc.'s Stock Performance As we look at the current performance of Rollins Inc. (NYSE: ROL), the shares are trading around $55.73, reflecting a decrease of 1.24% in the recent session. While the stock has dipped by 3.81% over the past month, it has impressively increased by 10.91% year-over-year. This presents a curious juxtaposition of short-term...

Continue Reading
Silver One Reports Major Mineral Resource Estimate for Candelaria

Updated Category News Views 199

Candelaria Project Mineral Resource Estimate Silver One Resources Inc. (OTCQX: SLVRF) has made a significant announcement regarding the completion of a mineral resource estimate for the Candelaria Project. This estimate is prepared in accordance with the National Instrument 43-101, ensuring that the resources are assessed with high standards of transparency and accuracy....

Continue Reading
Investors Alert: Zynex (ZYXI) Faces Serious Legal Scrutiny

Updated Category News Views 197

Legal Investigation into Zynex, Inc. The Law Offices of Frank R. Cruz have announced a crucial investigation regarding Zynex, Inc. (ZYXI) focused on potential violations of federal securities laws. This investigation comes as a response to significant concerns raised about the company's recent financial disclosures and their implications for investors. Understanding the...

Continue Reading
Understanding Rentokil Initial's Stock Valuation Insights

Updated Category News Views 100

Assessing Rentokil Initial's Stock Performance In the current trading session, Rentokil Initial Inc. (NYSE: RTO) shares are priced at $26.42, witnessing a notable increase of 1.46%. Over the past month, the stock has gained 1.40%, though it has faced a decline of 7.78% in the last year. This fluctuation raises questions among shareholders regarding its valuation, despite...

Continue Reading
Innovative Insights on Efzofitimod from aTyr Pharma's Recent Conference

Updated Category News Views 177

aTyr Pharma Highlights Efzofitimod at Key Conference At a significant scientific gathering, aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology firm known for its innovative therapeutic approaches, shared compelling data concerning efzofitimod. This presentation underlined important insights about the treatment of pulmonary sarcoidosis. The conference, which...

Continue Reading